论文部分内容阅读
目的观察利妥昔单抗与CHOP联合治疗复发难治CD20阳性B细胞型非霍奇金淋巴瘤的疗效和毒性反应。方法对13例复发难治的CD20阳性的B细胞型非霍奇金淋巴瘤采用利妥昔单抗与CHOP化疗联合方案,应用2周期后评价疗效及毒性反应。利妥昔单抗剂量为375mg/m2,CHOP化疗剂量为CTX750mg/m2,d1 iv EPI 60mg/m2,d1 iv VCR 1.4mg/m2,d1 iv PDN 100mg/d,d1-5 po。结果13例患者中有2例因经济原因1周期后中断治疗,其余11例均完成利妥昔单抗及CHOP方案化疗2周期(每3周重复1次),2例CR(18.18%),5例PR(45.45%),3例SD(27.27%),无PD病例,疾病控制(CR+PR+SD)率100%。治疗过程中出现的毒性反应较轻。全组患者无过敏反应。结论利妥昔单抗可提高肿瘤对化疗的敏感性。采用利妥昔单抗与CHOP联合化疗11例复发难治的CD20阳性的B细胞型非霍奇金淋巴瘤患者,取得初步疗效和安全性观察,且不因联合化疗而增加毒性反应,耐受性良好。
Objective To observe the curative effect and toxicity of rituximab combined with CHOP in the treatment of relapsed and refractory CD20 positive B cell non-Hodgkin’s lymphoma. Methods Thirteen patients with relapsed and refractory CD20 positive B-cell non-Hodgkin’s lymphoma were treated with rituximab combined with CHOP chemotherapy. The efficacy and toxicity were evaluated after two cycles. The dose of rituximab was 375 mg / m2, the dose of CHOP chemotherapy was CTX750 mg / m2, d1 iv EPI 60 mg / m2, d1 iv VCR 1.4 mg / m2, d1 iv PDN 100 mg / d, d1-5 po. Results Two of the 13 patients were discontinued after one cycle due to economic reasons. The remaining 11 patients completed two cycles of rituximab and CHOP regimen (once every 3 weeks), two CR (18.18%), 5 cases of PR (45.45%), 3 cases of SD (27.27%), no PD cases, disease control (CR + PR + SD) rate of 100%. Toxicity appears mild during treatment. All patients without allergic reaction. Conclusion Rituximab can increase the sensitivity of tumor to chemotherapy. Rituximab and CHOP combined chemotherapy in 11 patients with relapsed and refractory CD20-positive patients with B-cell non-Hodgkin’s lymphoma, initial efficacy and safety observed, and not because of combined chemotherapy and increased toxicity, tolerance Good sex.